Public Biotech Company Snapshots
Free public research snapshots for undercovered healthcare companies.
| Ticker | Company | Lead Asset | Indication | Stage | Next Catalyst | Runway |
|---|---|---|---|---|---|---|
| BIVI | BioVie Inc | NE3107 | Parkinson Disease | Phase 3 | 2026-08 | Runway 6-12 months |
| CVM | Cel-Sci Corp | CEL-SCI Corporation | Multikine Phase 3 Data Published in Peer-Reviewed Scientific Journal Pathology and Oncology Research | Phase 3 | 2026-08 | Runway < 6 months |
| ENSC | Ensysce Biosciences Inc | PF614 capsule | Postoperative Pain, Acute | Phase 3 | 2026-08 | Runway < 6 months |
| IGC | IGC Pharma Inc | Intellectual Property and Patents | Alzheimer | Approved | 2026-08 | Unknown |
| MBIO | Mustang Bio Inc | CD20 | n/a | Phase 1/2 | 2026-08-06 | Runway > 12 months |
| CRVO | CervoMed Inc | Mar 17 2026 | planned Phase 3 trial | Phase 3 | 2026-09 | Runway < 6 months |
| BOLD | Boundless Bio Inc | BBI-825 | Solid Tumor | Phase 1 | 2026-09-30 | Runway > 12 months |
| COCP | Cocrystal Pharma Inc | CC-42344 | Influenza A | Phase 2 | 2026-10-01 | Runway 6-12 months |
| CDT | CDT Equity Inc | Litifilimab | Subacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus Erythematosus | Phase 2 | Phase 3 | 2026-10-20 | Runway < 6 months |
| ATOS | Atossa Therapeutics Inc | ForeCYTE Breast Aspirator | Breast Neoplasms | Phase 3 | 2026-11 | Runway 6-12 months |
| KPRX | Kiora Pharmaceuticals Inc | KIO-301 | Late-stage Retinitis Pigmentosa (ABACUS-2) NCT06628947 | Phase 2 | 2026-11 | Runway > 12 months |
| MTVA | MetaVia Inc | DA-1726 | Obesity | Phase 1 | 2026-11-09 | Runway > 12 months |
| SKYE | Skye Bioscience Inc | GLP-1 | n/a | Approved | 2026-11-20 | Runway < 6 months |
| ALZN | Alzamend Neuro Inc | AL001 | Alzheimer's Disease | Healthy Non-elderly and Elderly Adults | Pivotal | 2026-12 | Runway < 6 months |
| BCDA | BioCardia Inc | Autologous cell therapy | Heart Failure, Systolic | Phase 3 | 2026-12 | Runway < 6 months |
| GOSS | Gossamer Bio Inc | Seralutinib | Pulmonary Arterial Hypertension | Phase 3 | 2026-12 | Runway 6-12 months |
| TRAW | Traws Pharma Inc | Rigosertib | Myelodysplastic Syndrome | Phase 2 | 2026-12 | Runway < 6 months |
| SER | Serina Therapeutics Inc | Cobimetinib | Melanoma | Phase 3 | 2026-12-08 | Runway > 12 months |
| SXTP | 60 Degrees Pharmaceuticals Inc | CELGOSIVIR | n/a | Approved | 2026-12-08 | Runway < 6 months |
| PBM | Psyence Biomedical Ltd | Psilocybin therapy | n/a | Phase 2 | 2026-12-30 | Unknown |
| ACTU | Actuate Therapeutics Inc | 9-ING-41 | Pancreatic Adenocarcinoma | Phase 2 | 2026-12-31 | Runway < 6 months |
| ATNM | Actinium Pharmaceuticals Inc | Video Gallery | n/a | Phase 3 | 2026-12-31 | Runway > 12 months |
| CALC | CalciMedica Inc | Auxora (Part 1) | Pneumonia | Phase 2 | 2027-01 | Runway < 6 months |
| INAB | IN8bio Inc | INB-400 | n/a | Phase 2 | 2027-01 | Runway > 12 months |
| INTS | Intensity Therapeutics Inc | INT230 | specific soft tissue sarcoma subtypes | Phase 3 | 2027-01 | Runway 6-12 months |
| AZTR | Azitra Inc | ATR12-351 | Netherton Syndrome | Phase 1 | 2027-01-15 | Runway 6-12 months |
| APLM | Apollomics Inc | Uproleselan | Relapsed/Refractory AML | Phase 3 | 2027-01-31 | Runway < 6 months |
| CELZ | Creative Medical Technology Holdings Inc | Infusion | n/a | n/a | 2027-01-31 | Runway > 12 months |
| GRCE | Grace Therapeutics Inc | Aprocitentan 12.5 mg | Resistant Hypertension | Phase 3 | 2027-02 | Runway > 12 months |
| RNTX | Rein Therapeutics Inc | Selinexor 60 mg | Myelofibrosis | Moderate Thrombocytopenia | Mild Thrombocytopenia | Phase 2 | 2027-02 | Runway < 6 months |
| XLO | Xilio Therapeutics Inc | XTX202 | Advanced Solid Tumor | Phase 1 | Phase 2 | 2027-02 | Runway > 12 months |
| LTRN | Lantern Pharma Inc | Putting LP-284 on the Industry RADR | n/a | Phase 3 | 2027-02-01 | Runway < 6 months |
| ATXS | Astria Therapeutics | Navenibart | Hereditary Angioedema | Phase 3 | 2027-03 | Unknown |
| MRKR | Marker Therapeutics Inc | bevacizumab | n/a | Phase 2 | 2027-03 | Runway > 12 months |
| TSHA | Taysha Gene Therapies | TSHA-102 | Rett Syndrome | Phase 3 | 2027-03-12 | Unknown |
| BOLT | Bolt Biotherapeutics Inc | BDC-1001 | Metastatic Breast Cancer | HER2-positive Breast Cancer | Phase 2 | 2027-05 | Runway 6-12 months |
| TELO | Telomir Pharmaceuticals Inc | Targeting Metal-Dependent Epigenetic Dysregulation | n/a | n/a | 2027-05 | Runway 6-12 months |
| CNSP | Cns Pharmaceuticals Inc | Levodopa-carbidopa intestinal gel | Advanced Parkinson's Disease | Phase 3 | 2027-06 | Runway < 6 months |
| SNSE | Sensei Biotherapeutics Inc | SNS-301 | Squamous Cell Carcinoma of the Head and Neck | Phase 2 | 2027-06 | Runway 6-12 months |
| TPST | Tempest Therapeutics Inc | Pentosan Polysulfate Sodium twice weekly | Osteoarthritis, Knee | Phase 3 | 2027-07 | Runway < 6 months |
| KTTA | Pasithea Therapeutics Corp | PAS-004 Capsules | RAS Mutation | NF1 Mutation | RAF Mutation | Advanced Solid Tumors | Phase 1 | 2027-09 | Runway > 12 months |
| OSTX | OS Therapies Inc | Trifluridine/Tipiracil | Refractory Metastatic Colorectal Cancer | Phase 3 | 2027-09 | Runway < 6 months |
| ACXP | Acurx Pharmaceuticals Inc | Ibezapolstat | Clostridium Difficile Infection | Phase 2 | 2027-09-29 | Runway > 12 months |
| DARE | Dare Bioscience Inc | We're On a Mission | n/a | Approved | 2027-10 | Runway > 12 months |
| VERU | Veru Inc | Eravacycline | Complicated Urinary Tract Infections | Phase 3 | 2027-10 | Runway > 12 months |
| JSPR | Jasper Therapeutics Inc | GFF MDI (PT 003) | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | 2027-11 | Runway < 6 months |
| MBRX | Moleculin Biotech Inc | Biospecimen Collection | Glioblastoma, IDH-Wildtype | MGMT-Unmethylated Glioblastoma | Phase 2 | 2027-12-27 | Runway < 6 months |
| APRE | Aprea Therapeutics Inc | ATRN-119 | n/a | Phase 2 | 2028-02 | Runway > 12 months |
| CLRB | Cellectar Biosciences Inc | NOV-205 | Hepatitis C | Phase 2 | 2028-02 | Runway < 6 months |
| NXTC | Nextcure Inc | Oxaliplatin | Pancreatic Cancer | Phase 2 | 2028-02 | Runway 6-12 months |
| GNPX | Genprex Inc | COVID-19 | pulmonary inflammation triggered by COVID-19 | Approved | 2028-03 | Runway > 12 months |
| RKTO | Rocket One Inc | Rocatinlimab | Atopic Dermatitis | Phase 3 | 2028-04 | Runway < 6 months |
| OTLK | Outlook Therapeutics Inc | Factor IX (rFIXFc) | Severe Hemophilia B | Phase 3 | 2028-05-31 | Runway < 6 months |
| CRIS | Curis Inc | CUDC-907 | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | Phase 2 | 2028-07-31 | Runway 6-12 months |
| HOWL | Werewolf Therapeutics Inc | WTX-330 | Advanced or Metastatic Solid Tumors | Non-Hodgkin Lymphoma | Phase 1 | 2028-08 | Runway 6-12 months |
| LITS | Lite Strategy Inc | Busulfan | Multiple Myeloma | Phase 2 | 2028-09 | Runway < 6 months |
| BCAB | BioAtla Inc | CAB-AXL-ADC | Non-Small-Cell Lung Cancer | Phase 2 | 2028-09-15 | Runway < 6 months |
| TOVX | Theriva Biologics Inc | VCN-01 | n/a | Phase 3 | 2029-09-30 | Runway 6-12 months |
| AIM | AIM ImmunoTech Inc | Ampligen | Chronic Fatigue Syndrome | Myalgic Encephalomyelitis | Phase 3 | 2029-12 | Runway < 6 months |
| PSTV | Plus Therapeutics Inc | Pirtobrutinib | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Phase 3 | 2030-04-01 | Runway 6-12 months |
| PASG | Passage Bio Inc | PBFT02 | n/a | Phase 1/2 | 2030-11-01 | Runway 6-12 months |
| SILO | SILO Pharma Inc | Unmet need | n/a | Approved | 2030-12-31 | Runway > 12 months |
| GTBP | GT Biopharma Inc | AL-335 | Chronic Hepatitis C | Phase 2 | 2031-01 | Runway < 6 months |
| LSTA | Lisata Therapeutics Inc | BOLSTER trial design | n/a | Approved | 2035-01 | Runway 6-12 months |
| GRI | GRI Bio Inc | Quadrivalent influenza modRNA vaccine | Influenza, Human | Phase 3 | 2037-11 | Runway 6-12 months |
| ABVC | ABVC BioPharma Inc | PDC-1421 Capsule | Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 2 | n/a | Runway < 6 months |
| ADIL | Adial Pharmaceuticals Inc | AD04 | AD04 Planned Phase 3 Trial Continue Reading | Registrational | Corporate Update | Runway 6-12 months |
| ADTX | Aditxt Inc | Laboratory assessment of antibody profiles | COVID-19 | n/a | n/a | Runway < 6 months |
| AEON | AEON Biopharma Inc | ABP-450 | Migraine | Phase 2 | n/a | Runway < 6 months |
| AKTX | Akari Therapeutics Plc ADR | n/a | n/a | n/a | n/a | Runway < 6 months |
| ALGS | Aligos Therapeutics Inc | COVID-19 | n/a | Phase 1 | n/a | Runway 6-12 months |
| ALLR | Allarity Therapeutics Inc | LiPlaCis ® | n/a | Phase 2 | n/a | Runway > 12 months |
| APVO | Aptevo Therapeutics Inc | The Molecule | n/a | Preclinical | n/a | Runway 6-12 months |
| ARTL | Artelo Biosciences Inc | ART12 | n/a | Approved | Data Readout | Runway 6-12 months |
| ASBP | Aspire Biopharma Holdings Inc | n/a | n/a | n/a | Corporate Update | Runway < 6 months |
| ATRA | Atara Biotherapeutics Inc | ATA3219 | n/a | Phase 1 | FDA Meeting | Unknown |
| BBLG | Bone Biologics Corp | Abatacept | Rheumatoid Arthritis (RA) | Phase 3 | n/a | Runway > 12 months |
| BRTX | BioRestorative Therapies Inc | Current Trials | study ID number | Phase 2 | Data Readout | Runway < 6 months |
| CDIO | Cardio Diagnostics Holdings Inc | n/a | n/a | n/a | n/a | Runway > 12 months |
| CELU | Celularity Inc | PDA-002 | Diabetic Foot Ulcers Complicated by Peripheral Artery Disease | Phase 2 | n/a | Runway < 6 months |